Research Report University Hospital for clinical evaluation of BAY 73-4506/15982

Abstract

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

Keywords

• Hepatocellular Carcinoma
• Regorafenib
• Sorafenib